

Tumor PD-L1 status and CD8⁺ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer

Supplementary Materials



Supplementary Figure 1: Overall survival outcome of stromal immune cell infiltrate. (A) TIL count (0.55 [0.33-0.96], P = 0.0335); (B) CD3⁺ T cell count (0.50 [0.29-0.87], P = 0.0139); (C) CD8⁺ T cell count (0.32 [0.22-0.71], P = 0.0020) and (D) FoxP3⁺ T cell count (0.63 [0.37-1.14], P = 0.1292). Cut-off values (low versus high) were taken at median values: 3⁺ (TIL count, CD3⁺ T cell count and CD8⁺ T cell count) and 2⁺ (FoxP3⁺ T cell count). TIL, tumor-infiltrating lymphocyte.



Supplementary Figure 2: Representative hematoxylin-eosin staining for presence of tumor infiltrating lymphocytes and CD3⁺ T cell count (x200). TIL count was scored semi-quantitatively as follows: (A) 1^+ , (B) 2^+ , (C) 3^+ and (D) 4^+ . CD3⁺ T cell count was scored semi-quantitatively as follows: (E) 1^+ , (F) 2^+ , (G) 3^+ and (H) 4^+ .

Supplementary Table 1: Disease-free survival

p .	Clinicopathological variables	P. J.
Parameter	Univariate HR (95% CI)	P-value
Age		
< 50 years	1	
50 – 69 years	0.65 (0.23–1.83)	0.3338
≥ 70 years	0.32 (0.08–1.28)	0.1368
T stage		
T1-2	1	
T3-4	1.58 (0.75–3.32)	0.2062
N stage		
N0	1	
N1	0.43 (0.12–1.49)	0.2534
N2-3	1.10 (0.50–2.42)	0.8096
Grade of differentiation		
Well / moderately	1	
Poorly	0.72 (0.30–1.73)	0.4939
Basaloid	0.45 (0.15–1.30)	0.2576
Primary treatment		
Surgery	1	
Radiotherapy	0.65 (0.26–1.71)	0.4001
Chemoradiotherapy	1.41 (0.60–3.55)	0.4036
Stromal immune cell infiltrate		
Parameter	Univariate HR (95% CI)	P-value
TIL count		
Low	1	
High	0.70 (0.32–1.50)	0.3548
CD3 ⁺ T cell count		
Low	1	
High	0.82 (0.37–1.81)	0.6107
CD8 ⁺ T cell count		
Low	1	
High	0.51 (0.23–1.38)	0.2050
FoxP3 ⁺ T cell count		
Low	1	
High	0.65 (0.29–1.51)	0.3280
Tumor		
Parameter	Univariate HR (95% CI)	P-value
HPV status		
Negative	1	
Positive	0.39 (0.20–1.16)	0.1033
SP142 PD-L1	(0.20 0.00)	
Low	1	
High	0.43 (0.22–1.16)	0.1070
22C3 PD-L1	(/
Low	1	
High	1.28 (0.60–2.83)	0.5110
Combination SP142 PD-L1 / CD8+ T cell count	1.20 (0.00 2.05)	0.5110
PD-L1 ⁻ /low CD8 ⁺	1	
At least 1 high	0.44 (0.21–1.11)	0.0849
At least 1 mgn Combination 22C3 PD-L1 / CD8 ⁺ T cell count	v. 44 (v.21–1.11)	0.0047
PD-L1 ⁻ / low CD8 ⁺	1	
		0.0167
At least 1 high	1.04 (0.46–2.36)	0.9167

Univariate HR was calculated via Kaplan-Meier survival analysis and log-rank test. Cut-off values were taken at median values (3 $^+$: abundant occurrence of TILs, CD3 $^+$ T cells and CD8 $^+$ T cells; and 2 $^+$: moderate numbers of FoxP3 $^+$ T cells) and at \geq 5% for PD-L1 on TCs (SP142 clone and 22C3 clone). Samples that were classified as 'impossible to evaluate' were not included in the survival analysis. HPV, human papillomavirus; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.